Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

BRCA2 gene mutation carriers at greater risk for more advanced prostate cancer

Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease.

10 Apr 2013

Nearly 50% of breast cancer patients at high risk of carrying BRCA mutation do not undergo genetic testing

Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation - based on age, diagnosis, and family history of breast or ovarian cancer - reported that their doctors urged them to be tested for the genes, according to a research team from the Perelman School of Medicine at the University of Pennsylvania.

9 Apr 2013

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

New drug combination shows anti-cancer activity in patients with solid tumors and germline mutation

A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

Dual-signaling CAR T cells show potent anti-cancer activity in animal model

The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs.

8 Apr 2013

New two-step immunotherapy approach offers new hope for ovarian cancer patients

As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today in a press conference at the AACR Annual Meeting 2013 (Presentation #LB-335).

8 Apr 2013

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Merrimack Pharmaceuticals, Inc. today announced that one cohort of a Phase 2 non-small cell lung cancer study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

5 Apr 2013

Wistar scientists describe mechanics of oncogene-induced senescence

Researchers from The Wistar Institute explain a new molecular mechanism behind the phenomenon of oncogene-induced senescence. By depriving the cell of the ability to make new nucleotides-the building blocks of DNA molecules-cells can suppress cancer development by forcing a damaged cell into a senescent state, where the cell remains alive yet cannot reproduce.

5 Apr 2013

New genetic variants may increase susceptibility to breast, prostate and ovarian cancers

The European Collaborative Oncological Gen-‐Environmental Study (COGS) project, whose main goal is to decipher the complex genetic bases of breast, prostate and ovarian cancers, publishes a total of 12 research articles in several prestigious journals, including Nature Genetics, Nature Communications, The American Journal of Human Genetics and PLOS Genetics.

4 Apr 2013

Illumina releases TruSight Tumor for NGS-based somatic variant detection in solid tumors

Illumina, Inc. today announced the next product in its TruSight line of content sets, TruSight Tumor, for NGS-based somatic variant detection in solid tumors.

From Illumina, Inc. 4 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

Researchers study effects of diet on cancer risk

Cancer is a disease that invokes fear, so it is not surprising that the public is eager to identify ways to decrease the risk. The media often features information on "Miracle Foods" and publicizes whether these foods can actually decrease the risk of cancer.

2 Apr 2013

States boost laws, regulations governing abortion

States have passed a record number of abortion bills since 2011, including curbs on clinics and chemically induced abortions and in North Dakota, a ban on abortions as early as six weeks.

2 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Researchers identify HNF1B gene that can increase risk of ovarian cancer

Researchers at Mayo Clinic Cancer Center have identified a novel gene that can contribute to a woman's susceptibility for developing ovarian cancer. Researchers identified the gene, called HNF1B, through large-scale analysis of more than 16,000 women with ovarian cancer and more than 26,000 healthy women.

28 Mar 2013

Study: New genetic variants may increase cancer risk

The European Collaborative Oncological Gen-Environmental Study (COGS) project, whose main goal is to decipher the complex genetic bases of breast, prostate and ovarian cancers, publishes today a total of 12 research articles in several prestigious journals, including Nature Genetics, Nature Communications, The American Journal of Human Genetics and PLOS Genetics.

28 Mar 2013

Study raises alarm over loss of individual 'genomic liberty' due to gene patents

Humans don't "own" their own genes, the cellular chemicsals that define who they are and what diseases they might be at risk for. Through more than 40,000 patents on DNA molecules, companies have essentially claimed the entire human genome for profit, report two researchers who analyzed the patents on human DNA. Their study, published March 25 in the journal Genome Medicine, raises an alarm about the loss of individual "genomic liberty."

27 Mar 2013

Research roundup: Nurse education and post-surgery mortality; The influence of publicly reported quality-of-care measures

Each week, KHN reporter Alvin Tran compiles a selection of recently released health policy studies and briefs.

16 Mar 2013

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

BRCA2 gene mutation carriers at greater risk for more advanced prostate cancer

Nearly 50% of breast cancer patients at high risk of carrying BRCA mutation do not undergo genetic testing

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

New drug combination shows anti-cancer activity in patients with solid tumors and germline mutation

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Dual-signaling CAR T cells show potent anti-cancer activity in animal model

New two-step immunotherapy approach offers new hope for ovarian cancer patients

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Wistar scientists describe mechanics of oncogene-induced senescence

New genetic variants may increase susceptibility to breast, prostate and ovarian cancers

Illumina releases TruSight Tumor for NGS-based somatic variant detection in solid tumors

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Researchers study effects of diet on cancer risk

States boost laws, regulations governing abortion

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Researchers identify HNF1B gene that can increase risk of ovarian cancer

Study: New genetic variants may increase cancer risk

Study raises alarm over loss of individual 'genomic liberty' due to gene patents

Research roundup: Nurse education and post-surgery mortality; The influence of publicly reported quality-of-care measures

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in